XGEVA®

ApprovedActive

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Giant Cell Tumor of Bone

Conditions

Giant Cell Tumor of Bone

Trial Timeline

Aug 17, 2023 → Mar 7, 2028

NCT ID

NCT04586660

About XGEVA®

XGEVA® is a approved stage product being developed by Amgen for Giant Cell Tumor of Bone. The current trial status is active. This product is registered under clinical trial identifier NCT04586660. Target conditions include Giant Cell Tumor of Bone.

What happened to similar drugs?

4 of 13 similar drugs in Giant Cell Tumor of Bone were approved

Approved (4) Terminated (3) Active (7)

🔄PexidartinibDaiichi SankyoPhase 3

✅PexidartinibDaiichi SankyoApproved

🔄Upadacitinib + Corticosteroid (CS)AbbViePhase 3

🔄Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c.NovartisPhase 3

🔄Secukinumab 300 mg + Secukinumab 150 mgNovartisPhase 3

🔄Tocilizumab + PlaceboRochePhase 3

✅Tocilizumab + PrednisoneRocheApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04586660	Approved	Active	Aug 17, 2023	Mar 7, 2028	Giant Cell Tumor of Bone

Competing Products

20 competing products in Giant Cell Tumor of Bone

See all competitors

Product	Company	Stage	Hype Score
prednisone	Kiniksa Pharmaceuticals	Phase 2	29
Pexidartinib	Daiichi Sankyo	Phase 2	39
Pexidartinib	Daiichi Sankyo	Phase 3	44
Pexidartinib	Daiichi Sankyo	Approved	43
Baricitinib	Eli Lilly	Phase 2	35
Upadacitinib + Corticosteroid (CS)	AbbVie	Phase 3	40
dovitinib	Novartis	Phase 2	35
Secukinumab 300 mg, s.c. + Placebo to match Secukinumab, s.c.	Novartis	Phase 3	40
Secukinumab 300 mg, s.c. + Prednisolone + Placebo	Novartis	Phase 2	35
Secukinumab	Novartis	Phase 1	29
Secukinumab 300 mg + Secukinumab 150 mg	Novartis	Phase 3	40
Tocilizumab + Placebo	Roche	Phase 3	44
Tocilizumab + Prednisone	Roche	Approved	43
Tocilizumab	Roche	Phase 3	40
Tocilizumab	Roche	Phase 1	29
Valganciclovir	Roche	Approved	35
Tocilizumab + Prednisone + Tocilizumab Placebo + Prednisone Placebo + Corticosteroids + Methotrexate	Roche	Phase 3	40
Tocilizumab + Glucocorticoids (GCs) + Placebo + Glucocorticoids (GCs)	Roche	Phase 2	35
tocilizumab and IV steroids combination	Roche	Phase 2	31
Denosumab	Amgen	Approved	43